1 WHO. State of the art of new vaccines (www.who.init/vaccine_research/documents/new_vaccines/en/). World Health Oganisation Initiative for Vaccine Research, 2003.
2 Cane PA. Molecular epidemiology of respiratory syncytial virus. Rev Med Virol 2001; 11: 103–116.
3 Mufson M, Orvell C, Rafnar B, Norrby E. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 1985; 66: 2111–2124.
4 Johnson PR, Collins PL. The fusion glycoproteins of human respiratiry syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness. J Gen Virol 1988; 69: 2623–2628.
5 Glezen W, Taber L, Frank A, Kasel J. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140: 543–546.
6 Hall C, Geiman J, Biggar R, Kotok D, Hogan P, Douglas RJ. Respiratory syncytial virus infections within families. New Engl J Med 1976; 294: 414–419.
7 Henderson F, Collier A, Clyde WJ, Denny F. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. New Engl J Med 1979; 300: 530–534.
8 Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001; 33: 792–796.
9 Falsey AR, Walsh EE. Respiratory syncytial virus in adults. Clin Microbiol Rev 2000; 13: 371–384.
10 Chanock R, Kim H, Vargosko A, et al. Respiratory syncytial virus. 1. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children. J Am Med Assoc 1961; 176: 647–653.
11 McCarthy CA, Hall CB. Respiratory syncytial virus: concerns and control. Pediatr Rev 2003; 24: 301–309.
12 Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus. In: Howley PM, ed. Fields virology. Philadelphia: Lippincott-Raven, 2001: 1443–1485.
13 Sullender W. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 2000; 13: 1–15.
14 Cane P, Matthews D, Pringle C. Analysis of respiratory syncytial virus strain variation in successive epidemics in one city. J Clin Microbiol 1994; 32: 1–4.
15 Waris M. Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B. J Infect Dis 1991; 163: 464–469.
16 Carbonell-Estrany X, Quero J, Bustos G, et al. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001; 20: 874–879.
17 Weber MW, Milligan P, Hilton S, et al. Risk factors for severe respiratory syncytial virus infection leading to hospital admission in children in the Western Region of The Gambia. Int J Epidemiol 1999; 28: 157–162.
18 Keeling MJ, Rohani P, Grenfell BT. Seasonally forced dynamics explored as switching between attractors. Physica D 2001; 148: 317–335.
19 Andreassen V, Lin J, Levin SA. The dynamics of cocirculating influenza strains conferring partial cross-immunity. J Math Biol 1997; 35: 825–842.
20 Gomes MGM, Medley GF, Nokes DJ. On the determinants of population structure in antigenically diverse viral pathogens. Proc R Soc Lond (Series B) 2002; 269: 227–233.
21 Weber A, Weber M, Milligan P. Modelling epidemics caused by respiratory syncytial virus (RSV). Math Biosci 2001; 172: 95–113.
22 Gomes MGM, Medley GF. Dynamics of multiple strains of infectious agents coupled by cross-immunity: a comparison of models. In: Yakubu AA, ed. Mathematical approaches for emerging and reemerging infectious diseases. The IMA Volumes in Mathematics and its Applications, Vol. 126. New York: Springer-Verlag, 2002.
23 White LJ, Schukken YH, Lam TJGM, Medley GF, Chappell MJ. A multispecies model for the transmission and control of mastitis in dairy cows. Epidemiol Infect 2001; 127: 567–576.
24 Roca A, Abacassamo F, Loscertales MP, et al. Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. J Med Virol 2002; 67: 616–623.
25 Brandenburg A, Groen J, Steensel-Moll Hv, et al. Repiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997; 52: 97–104.
26 UN Indicators on Population (http:/www.un.org/Depts/unsd/social/population.htm). United Nations Statistics Division, 2002.
27 Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O. Hospitalisation of high-risk infants for RSV infection: implications for palivizumab prophylaxis. Archives Dis Childhood 2004 (in press).
28 Macey R, Oster G, Zahnley T. Berkeley Madonna (Version 7.0). University of California, 1999.
29 Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical recipes in C: the art of scientific computing, 2nd edn. Cambridge: Cambridge University Press, 1992.
30 The Mathworks I. Matlab. 6.5.0.196271 (R13.0.1) edn.
31 Anderson RM, May RM. Infectious diseases of humans dynamics and control. Oxford University Press, 1991.
32 Fine PEM, Clarkson JA. Measles in England and Wales I: An analysis of factors underlying seasonal patterns. Int J Epidemiol 1982; 11: 5–14.
33 White LJ, Cox MJ, Medley GF. Cross immunity and vaccination against multiple parasite strains. IMA J Math Applied Med Biol 1998; 15: 211–233.
34 Nokes DJ, Okiro E, Ngama MJ, et al. Respiratory syncytial virus epidemiology in a birth cohort from Kilifi District, Kenya: infection in the first year of life. J Infect Dis 2003; 190: 1828–1832.
35 Grenfell BT, Pybus OG, Gog JR, et al. Unifying the epidemiological and evolutionary dynamics of pathogens. Science 2004; 303: 327–332.
36 Martinello RA, Chen MD, Weibel C, Kahn JS. Correlation between respiratory syncytial virus genotype and severity of illness. J Infect Dis 2002; 186: 839–842.
37 Brandenburg AH, van Beek R, Moll HA, Osterhaus A, Claas ECJ. G protein variation in respiratory syncytial virus group A does not correlate with clinical severity. J Clin Microbiol 2000; 38: 3849–3852.
38 Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003; 143: S118–S126.
39 McLean AR. Vaccination, evolution and changes in the efficacy of vaccines: a theoretical framework. Proc R Soc Lond (Series B) 1995; 261: 389–393.